Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)ACIP: Updated Vaccine Guidance for the 2023-2024 Influenza Season

Primary updates include the composition of the 2023-2024 vaccine, as well as new guidance for patients with egg allergy.

The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has updated its guidance for the 2023-2024 influenza season. The ACIP now recommends that all patients 6 months of age and older who have no contraindications receive an influenza vaccine.

Key Points:
  • The ACIP recommends that all patients 6 months of age and older who have no contraindications receive an influenza vaccine.
  • The vaccine should ideally be administered by October, but it can be given throughout the influenza season if influenza viruses are still circulating.
  • The ACIP now recommends that all persons 6 months of age and older with egg allergy receive influenza vaccine, regardless of the severity of their previous reaction to egg.
  • It is no longer recommended that individuals who have had an allergic reaction to egg with symptoms other than urticaria should be vaccinated in a medical setting supervised by a health care provider.
  • There is no evidence for interference in the immune response to either influenza or RSV vaccine when they are administered together.
Additional Points:
  • The ACIP also recommends that pregnant women get vaccinated against influenza.
  • The ACIP recommends that children 6 months of age and older get vaccinated against the new respiratory syncytial virus (RSV) vaccine.
  • The ACIP recommends that adults 65 years of age and older get a high-dose influenza vaccine.

More on Influenza

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form